Resection of retroperitoneal sarcoma (RPS) typically involves multivisceral resection.
| INTRODUCTION
Surgery is the mainstay of curative-intent treatment for retroperitoneal sarcoma (RPS). Given that these tumors typically grow to a considerable size prior to detection and can often involve multiple organs, definitive surgery frequently requires a complex, multivisceral resection. In order to devise tailored treatment strategies for individual patients and to counsel them accordingly, sarcoma surgeons must be able to appreciate the anticipated morbidity of a proposed procedure. The literature surrounding the short-and long-term outcomes following resection of RPS is scant and limited by considerable heterogeneity in patient populations and surgical approach. Accepting these limitations, the data available to guide decision-making are reviewed here.
| EXTENT OF SURGERY AND SHORT-TERM MORBIDITY
Over the past decade, there has been a paradigm shift toward a radical surgical approach to RPS. In 2009, two European centers published data suggesting improved oncologic outcomes with liberal en bloc resection of organs adhering to, but not necessarily invaded by, RPS.
1,2
Gronchi et al reported significantly reduced local recurrence rates with radical resection compared to an historical cohort who underwent marginal excision at the same institution. With longer follow-up, this improvement in local control was found to be associated with improved overall survival. 3 The evolution toward more radical resection generated debate regarding the expectation of increased operative morbidity and whether this might offset or even negate any oncologic benefit. 4, 5 This question was investigated by the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG), an international collaboration of sarcoma centers. The eight founding centers pooled their contemporary 10-year data to generate the largest reported experience of RPS resection to date. 6 A total of 1007 patients underwent resection for primary, localized RPS from 2002 to 2011. All centers ascribed to a radical resection philosophy, with a median of two organs resected. The 30-day mortality rate in this series was 1.8%, with 16.4% of patients suffering a major complication (Clavien-Dindo ≥3) and bleeding/hematoma (2.9%), gastrointestinal (GI) anastomotic leak (2.6%), and death (1.8%). A resected organ score was devised to account for differential morbidity in organ resection. Organs were weighted according to anticipated morbidity, with pancreaticoduodenectomy assigned a higher score than nephrectomy, for example, and organs whose resection were felt to confer no added morbidity such as the appendix were weighted zero. Resected organ score was a significant predictor of morbidity, as were age >65 and transfusion requirements. This study also investigated common patterns of multivisceral resection and found that those involving pancreaticoduodenectomy, vascular resection, and the combination of colon, kidney, spleen, and pancreas were associated with severe adverse events. Administration of preoperative chemo-or radio-therapy was not associated with increased post-operative morbidity, indicating that these patients can be safely treated with multimodal therapy as appropriate without impacting on the surgical strategy. Importantly, this study also demonstrated no impact of adverse events on overall survival and rates of local recurrence and distant metastases, suggesting that there is no oncologic penalty to be paid for operative morbidity.
The TARPSWG experience represents the largest series of RPS to report on operative morbidity and has the advantage of granular operative details not available in other series. It also reflects outcomes in the modern era, with advances in surgical techniques and perioperative care compared to historical series.
Three TARPSWG centers have reported separately on their shortterm post-operative outcomes, with some overlap between these series and the above described collaborative data. The French and 1997, of whom 77% had at least one organ resected. 12 Mortality in this population was 4% at 30 days. These historical series all report higher early post-operative mortality rates than contemporary data, despite the fact that these patients for the most part underwent more conservative operations.
A more recent study compared alternative surgical approaches based on histologic subtype. 13 Given the rarity of RPS as well as the complexity and multidisciplinary nature of its treatment, it is recommended that these patients be managed within specialist sarcoma centers. 20 The majority of RPS were recurrent (68%) and the patients who received IORT were carefully selected on the basis of a perceived high risk of positive margins following EBRT and radical resection. Severe post-operative complications (Clavien-Dindo ≥3) occurred in 34% of patients. Similarly, an ongoing phase I/II trial of preoperative intensity-modulated radiotherapy (IMRT) followed by IORT and radical resection reported an unplanned interim safety analysis in 2014 in which 33% suffered major morbidity, 15% required reoperation, and post-operative mortality was 7%, albeit beyond 30 days. 21 In both of these recent series, the morbidity following preoperative EBRT + IORT is twice that seen in the TARPSWG experience with radical resection +/− EBRT.
Smith et al reported the long-term results of a phase II trial adding postoperative brachytherapy to preoperative EBRT and found no benefit in terms of local control but prohibitive toxicities. 22 Treatmentrelated mortality was 7.5% at 18 months median follow-up, and severe late toxicities (RTOG grade ≥3) persisted in 11% of alive patients beyond this time point. Specifically, duodenal stricture was a serious complication in patients treated with brachytherapy in the upper abdomen.
Based on these available data, a consensus document from the TARPSWG stipulated that preoperative EBRT may be considered as a neoadjuvant strategy for well-selected patients within experienced centers. 23 IORT may be considered if a specific margin is considered at risk, although from a practical point of view the field often is too large for its application, and it is considered to be of no study-proven value.
Finally, postoperative RT is discouraged due to excessive morbidity and the improbability of achieving a therapeutic dose.
| LONG-TERM MORBIDITY FOLLOWING RESECTION OF RPS

| Renal function following nephrectomy
The long-term sequelae of RPS resection, especially those involving contiguous organ resection, have not been extensively studied. As survival improves to a median of 67% at 5 years for all subtypes and more than 80% at 10 years for WD LPS. 24 the long-term disability related to disease management is of increasing concern. In particular, the risk of renal failure following nephrectomy has prompted some centers to advocate for kidney-sparing resections.
A retrospective analysis of long-term renal function after RPS resection with nephrectomy has been reported in a series of 54 patients operated on at Massachusetts General Hospital. 25 Median eGFR decreased from 85 mL/min to a nadir of 44 mL/min postopera- Renal function after multivisceral resesction for RPS was also documented by the Milan group in a retrospective analysis of 95 longterm survivors. 26 Nephrectomy was performed in 67% of cases. After nephrectomy, creatinine concentration was within 1.5 times the upper reference limit in 91% of patients both at 4 months after surgery and at a distant time point (median 49 months). In multivariable analysis, adjusting for patient age and baseline levels, creatinine did not differ between patient who underwent nephrectomy and those who did not. The only available QOL data prospectively collected at baseline in primary RPS patients proceeding to surgery were recently presented by Fiore et al. 27 Sixty consecutive patients were enrolled of whom 25% received neoadjuvant treatment (7 radiotherapy, 6 chemotherapy, 2 chemo + radiotherapy). Prior to surgery, Global Health Status (GHS) scores were evaluated by the EORTC QLQ-C30, on a scale from 0 to 100. The median score was 
| Pain, function, and quality of life
| SURGERY FOR RPS IN THE ELDERLY
Given the extent of surgery required for complete resection of RPS and the above described operative risks, careful preoperative assessment is required to ensure that patients are suitable candidates and are optimized for the procedure. Advanced age is of concern in undertaking any major abdominal operation and the elderly deserve particular attention in discussion of surgery for RPS.
In the Royal Marsden Hospital series of RPS resections from 2005 to 2014, the only significant predictor of 30-day mortality was age >75. 8 This prompted further investigation into decision-making regarding surgery for RPS in the elderly, as well as outcomes in this population. Smith et al reported a significantly higher rate of nonoperative management for RPS in patients >65 (41.8% vs 12.0%, P < 0.001) despite similar rates of unresectable tumors as compared to younger patients. 28 This disparity was attributed to comorbidities and patient preference. Elderly patients who did undergo surgery suffered significantly higher rates of post-operative complications than patients <65 (28.3% vs 9.5%, P < 0.001), although mortality was the same. Importantly, oncologic outcomes were nonetheless equivalent between the two groups. Similarly, the TARPSWG collaboration identified age >65 as a significant prognostic factor for postoperative morbidity (OR 1.50, 95% CI 1.06-2.13; P = 0.031) and concluded that patients must not be excluded from consideration for RPS resection on the basis of age alone, but that the increased risks associated with advanced age warrant specific patient counselling.
An attempt to risk-stratify patients undergoing resection for RPS using the modified frailty index (mfI) was recently reported by Park et al. 29 Using data from the ACS-NSQIP database, RPS patients were found to have low mfI scores (ie, few comorbidities). Select mfI scores were associated with severe morbidity but did not predict 30-day mortality. Overall this was not shown to be a robust tool for the RPS population.
| SURGERY FOR RECURRENT RPS
To date, radical multivisceral resection has only been shown to be of value in primary RPS. Decision-making regarding resection of recurrent RPS is complex and multifactorial. When appropriate, the goal of surgery is complete resection (R0/1), with contiguous organs removed only as necessary. 30 Despite re-resection, post-relapse outcomes are poor, with the vast majority of patients developing further recurrence. 31 For this reason, decisions regarding resection of recurrent disease must carefully weigh anticipated morbidity against the perceived benefit, taking into account that the probability of cure is extremely low.
Data regarding morbidity of resection for recurrent RPS are extremely scant. In the Heidelberg series, there was no difference in morbidity and mortality for primary versus recurrent RPS, although differences in surgical approach are not described. evidence available appears to demonstrate acceptable morbidity.
Renal function following nephrectomy is adequate, with typically only mild impairment of no functional consequence. Subjectively reported rates of sensory disturbance and pain are high and require further investigation, both to document these phenomena prospectively and to investigate surgical techniques that might modify these risks (eg, nerve preservation). Quality of life data are scant but promising.
The systematic and prospective collection of metrics for shortand long-term morbidity, functional outcomes, and QOL should be undertaken by all sarcoma centers in order to achieve an accurate and comprehensive understanding of the impacts of RPS and its treatment.
This will require the development or validation of specific instruments for this disease. Simultaneously, sarcoma centers should be continuously refining and improving surgical techniques, actively advancing learning curves, and ensuring the highest quality standards in perioperative management.
